High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost

In an editorial accompanying the study, Dr. Khosla noted that 15 months of the higher-dose therapy would cost $76,000, which would be expected to decline after teriparatide went off patent in August 2019, “although considering recent trends in generic drug pricing, a price decrease is by no means certain.”²

The National Institutes of Health and the Dart Foundation funded the research.

References

1. Tsai JN, Lee H, David NL, et al. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): A randomized, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019 Aug 22. pii: S2213-8587(19)30255-4. [Epub ahead of print]
2. Khosla S. Personalizing osteoporosis treatment for patients at high risk of fracture. Lancet Diabetes Endocrinol. 2019 Aug 22. pii: S2213-8587(19)30266-9. [Epub ahead of print]